Results 221 to 230 of about 579,513 (302)

FIBRINOLYTIC ACTNITY IN INFLAMATORY BOWEL DISEASE

The Turkish Journal of Gastroenterology, 1994
Uğur YILMAZ, Selim AYAZ, Ahmet TEZEL, Hülya ÖVER, Azmi SERİN, Leziz ONARAN   +5 more
doaj  

Neutrophil migration participates in the side effect of recombinant human tissue plasminogen activator. [PDF]

CNS Neurosci Ther
Huang Y, Han Z, Shen T, Zheng Y, Yang Z, Fan J, Wang R, Yan F, Tao Z, Luo Y, Liu P.   +10 more
europepmc   +1 more source

Bidirectional Relationship and Shared Mechanisms Between Sarcopenia and Osteoporosis: An Observational Study Integrating Genomic, Proteomic, and Metabolomic Data

Aging Cell, Volume 25, Issue 7, July 2026.
This study investigated the bidirectional relationship and shared mechanisms between sarcopenia and osteoporosis using data from the UK Biobank. Our findings indicated that the two conditions may act as reciprocal risk factors, with multiple potential biomarkers mediating the muscle‐bone relationship and suggested possible shared signals between the ...
Siqi Xu, Simin Wen, Xizeng Zong, Jianwei Zhu, Qiuling Du, Yu Li, Kunyan Wang, Peihua Cao, Changhai Ding, Yan Zhang, Guangfeng Ruan   +10 more
wiley   +1 more source

Correlation between subretinal tissue plasminogen activator and air injection rates with pressure in a retina mimicking model. [PDF]

Sci Rep
Kim NH, Lee M, Chung H, Kim HC, Lee H.
europepmc   +1 more source

Use of recombinant tissue plasminogen activator (rTPA) for treatment of fibrin in the anterior chamber of the horse. [PDF]

Vet Med Sci
Pereira R, Bowen M, Rapezzano G, Redpath A, Pratt S, Hallowell G.   +5 more
europepmc   +1 more source

A novel technique for extensive submacular hemorrhage using high-dose tissue plasminogen activator. [PDF]

Indian J Ophthalmol
Chauhan K, Narayanan R.
europepmc   +1 more source

Mechanical Tricuspid Valve Thrombosis Successfully Treated With Tissue Plasminogen Activator. [PDF]

JACC Case Rep
Haraf R, Atkinson T, Elizabeth Le DT, Arora B.   +3 more
europepmc   +1 more source

Pharmacokinetics and pharmacodynamics of low doses of recombinant tissue plasminogen activator to establish a model for biosimilarity comparisons. [PDF]

Res Pract Thromb Haemost
Derhaschnig U, Buchtele N, Steiner MM, Drucker C, Firbas C, Schörgenhofer C, Gelbenegger G, König F, Jilma B, Kovacevic Miljevic KD.   +9 more
europepmc   +1 more source

Tissue Plasminogen Activator or Perfluoropropane for Submacular Hemorrhage in Age-Related Macular Degeneration: A Factorial Randomized Clinical Trial.

JAMA Ophthalmol
Murphy GSP, Saleh A, Ayis S, Cheema MR, Mehta A, Steel DH, Membrey L, Costen M, Jackson TL.   +8 more
europepmc   +1 more source